Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses recent advances in the use of antibodies for the treatment of multiple myeloma, highlighting the promise of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), as well as bispecifics. Prof. Raje first comments on the movement of mAbs into the frontline setting and advances in quadruplet regimens. Following this, Prof. Raje highlights the DETERMINATION trial (NCT01208662), and further discusses the use of ADCs, such as belantamab mafodotin, as a single agent and in combination with other agents. To conclude, Prof. Raje discusses the promise of bispecific antibodies including teclistamab and elranatamab, and their place in the myeloma treatment landscape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, outlines new agents added to induction strategies in patients with newly diagnosed transplant-eligible multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
In this video, Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses the potential role of histone deacetylase (HDAC) inhibitors for the treatment of multiple myeloma (MM). Although these agents have not been widely used, Dr Ocio explains that there may still be a niche for HDAC inhibitors in combination with other agents in the myeloma treatment landscape. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the DETERMINATION trial (NCT01208662) evaluating the use of lenalidomide, bortezomib, and dexamethasone versus high-dose treatment with autologous stem cell transplantation (autoSCT) in patients with multiple myeloma. Dr Richardson first highlights some results from this trial, including the progression-free survival (PFS) observed in patients and the importance of transplant in controlling event-free survival (EFS). Dr Richardson then discusses the toxicities observed and further highlights other therapies changing the myeloma treatment landscape, including quadruplet therapies, monoclonal antibodies, CAR-T therapy, and bispecific T-cell engagers (BiTEs). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
In this video, Joan Bladé, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the management and treatment of renal impairment in patients with multiple myeloma. Prof. Bladé first highlights the poorer outcomes associated with patients who present with severe renal impairment, and then discusses potential treatment combinations, including bortezomib plus dexamethasone and a third agent. Following this, Prof. Bladé shares some insights into his presentation at COMy 2022, which focused on a long-term follow-up of patients with renal impairment and the improvements that have been made in these patients over the last 50 years. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, shares some recent updates on cereblon E3 ligase modulators (CELMoDs) for multiple myeloma and how these novel agents are transforming the treatment landscape. Prof. Lonial first reports on some data on the use of iberdomide plus dexamethasone in patients with triple-class refractory disease. Following this, Prof. Lonial discusses the encouraging activity observed in various CELMoDs and compares this to the use of immunomodulatory imide drugs (IMiDs). To conclude, Prof. Lonial discusses the activity and safety profile of CC-92480 and the impact that CELMoDs will have on the myeloma treatment landscape. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
In this video, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the future treatment of myeloma and his presentation at COMy 2022. Dr Anderson highlights his presentation which covered a variety of topics, including novel technologies used to monitor myeloma, the application of therapeutic agents, advances in immunotherapy, and novel targets. Dr Anderson then goes on to discuss precision medicine and the role of novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, antibodies, bispecific T-cell engagers (BiTEs), and the importance of achieving measurable residual disease (MRD) negativity. To conclude, Dr Anderson addresses the possibility of achieving cure in myeloma by 2030. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, gives an update on the CARTITUDE-5 study (NCT04923893), which compares the efficacy of bortezomib, lenalidomide and dexamethasone (VRd) induction therapy followed by ciltacabtagene autoleucel (cilta-cel) or lenalidomide and dexamethasone maintenance (Rd) in patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible or that have deferred transplantation until first relapse. The primary endpoint is measurable residual disease (MRD) negativity and secondary endpoints include overall response rate (ORR) and overall survival (OS). The results from this trial are eagerly awaited and could potentially be practice-changing. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, outlines treatment options for patients with multiple myeloma with 17p deletion, highlighting key clinical trials. Numerous studies have demonstrated that this patient population has a poorer prognosis compared to other patients with multiple myeloma. The HOVON-65/GMMG-HD4 study (EudraCT 2004-000944-26) and the TOURMALINE-MM1 study (NCT01564537) have reported a survival benefit for patients with del(17p) receiving continuous bortezomib treatment and ixazomib in combination with lenalidomide and dexamethasone respectively, suggesting the combination of a proteasome inhibitor with an immunomodulatory agent as a promising treatment option for these patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses key advances in the management of multiple myeloma. In recent years, the introduction of anti-BCMA monoclonal antibodies and chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape of multiple myeloma. Prof. Pratt also mentions the approval of the quadruplet combination of daratumumab, bortezomib, thalidomide and dexamethasone (D-VTd) in the UK. Moving forward, Prof. Pratt highlights various areas of ongoing research in multiple myeloma, including treatment sequencing, risk-adapted therapy in young patients, dose adjustments and frailty assessment in elderly patients, which is currently evaluated in the FiTNEss trial (NCT03720041), and the potential role of measurable residual disease (MRD) as a clinical endpoint, which is currently being assessed in the RADAR trial (ISRCTN46841867; UK-MRA Myeloma XV).
Maximilian Merz, MD, Leipzig University, Leipzig, Germany, Roswell Park Comprehensive Center Institute, Buffalo, NY, comments on the management of patients with multiple myeloma not eligible for transplant, where a paradigm shift has been observed after the introduction of CD38 antibodies to upfront therapy, with higher rates of progression-free survival (PFS) and overall survival (OS) and long-lasting remissions. Data from the ALCYONE (NCT02195479) and MAIA (NCT02252172) trials led to the approval of several combinations of daratumumab, with a notable outcome improvement in elderly and frail patients. Dr Merz considers that the standard of care should point to antibody plus lenalidomide-dexamethasone (Rd) or bortezomib-melphalan-prednisone (VMP), but more data on quadruplet therapy for ineligible patients is needed. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses antibody-drug conjugates (ADCs) and their importance in the treatment of multiple myeloma. Dr Popat first highlights some of the novel therapies that have greatly impacted myeloma treatment, including proteasome inhibitors (PIs), immunomodulatory imide drugs (IMiDs), and monoclonal antibodies. Dr Popat then explains the emergence of ADCs, drawing focus on belantamab mafodotin, which has been approved and has shown promising results in the Phase II DREAMM-2 trial (NCT03525678). Following this, Dr Popat highlights some of the results from this study, including overall response rate (ORR) and the management of adverse events (AEs). To conclude, Dr Popat discusses the potential combination of belantamab mafodotin with other standard of care agents, such as bortezomib and lenalidomide. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.